Outcome of Transarterial Chemoembolization (TACE) in Patients with Hepatocellular Carcinoma | ||||
| The Medical Journal of Cairo University | ||||
| Article 153, Volume 87, December, December 2019, Page 5293-5297 PDF (432.29 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjcu.2019.89785 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| ALI A.S. GHWEIL, M.D.; AHMED O. MOHAMED, M.D.; SHAMARDAN EZZELDIN S. BAZEED, M.D.; AHMED A.A. MOHAMMED, M.Sc. | ||||
| The Departments of Tropical Medicine & Gastroenterology* and Radiology**, Faculty of Medicine, Qena University | ||||
| Abstract | ||||
| Abstract Background: Transarterial Chemoembolization (TACE) is recommended as a treatment for unresectable Hepatocellular Carcinoma (HCC) in patients with normal compensated liver. The efficacy of TACE in cirrhotic patients with compromised liver function is unknown. Aim of Study: To evaluate the outcome following Tran-sarterial Chemoembolization (TACE) in patients with unap-plicable locoregional therapy in Hepatocellular Carcinoma (HCC). Patients and Methods: This Prospective Cohort study conducted on 50 patients with HCC at Tropical Medicine and Gastroenterology Department Qena University Hospital. Results: 56% of patients reached complete response within one month of treatment in mean duration of follow-up of 58.28 months, 66% of patients had recurrence 40% in <1 year and 26% 1-2 years, 34% of recurrence were target tumor progression, 20% intrahepatic new lesion and 12% both, total deaths were 46% of patients. Conclusions: TACE offers a reasonable palliative therapy for HCC. | ||||
| Keywords | ||||
| Transarterial Chemoembolization (TACE); HCC | ||||
|
Statistics Article View: 184 PDF Download: 239 |
||||
